A Novel Technology for Engineering Binders to Membrane Proteins

Information

  • Research Project
  • 10227122
  • ApplicationId
    10227122
  • Core Project Number
    R21GM138811
  • Full Project Number
    5R21GM138811-02
  • Serial Number
    138811
  • FOA Number
    PAR-19-254
  • Sub Project Id
  • Project Start Date
    8/1/2020 - 6 years ago
  • Project End Date
    7/31/2022 - 4 years ago
  • Program Officer Name
    WU, MARY ANN
  • Budget Start Date
    8/1/2021 - 5 years ago
  • Budget End Date
    7/31/2022 - 4 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/4/2021 - 5 years ago
Organizations

A Novel Technology for Engineering Binders to Membrane Proteins

Antibodies have been coined the ?magic bullets? against many human diseases. However, there remains significant challenges in the engineering of antibodies targeting multi-pass membrane proteins, which encompass a large number of therapeutic targets such as cell surface receptors and the ion channel proteins. The difficulty in engineering binders to membrane proteins stems from the limitation of the current in vitro selection/panning technologies, such as phage display, which require highly purified target protein. Unfortunately, membrane proteins are often refractory to purification due to their dependence on the cell membrane for proper folding and activity. Currently, there is no effective in vitro technology for the discovery/engineering of binders to multi-pass membrane proteins. The overall goal of this study is to develop a novel technology ? SMURF (Simple proxiMity coUpled mRNA display) ? for engineering protein binders to protein targets on the cell surface, thus bypassing the need to purify the target protein. SMURF combines mRNA display with the proximity-assisted-DNA-assembly phenomenon and, unlike conventional panning in which all binders to a solid support are enriched, SMURF fosters the enrichment of binders only to a desired target protein on the cell surface. In Aim 1, we will demonstrate the SMURF principle using oligonucleotides and optimize the primer sequences. Aim 2 will establish the SMURF enrichment of a model protein in a mixture of non-target proteins in solution. Finally, in Aim 3, a model protein will be displayed on the mammalian cell surface and a library of binders will be screened to demonstrate and quantify the whole-cell SMURF enrichment efficiency. The successful completion of this study will establish a novel technology for facile discovery/engineering of binders to whole-cell-displayed membrane proteins and should greatly expand the repertoire of drug targets amenable to therapeutic intervention.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R21
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    125000
  • Indirect Cost Amount
    64375
  • Total Cost
    189375
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIGMS:189375\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    DMP
  • Study Section Name
    Drug Discovery and Molecular Pharmacology Study Section
  • Organization Name
    TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
  • Organization Department
    MICROBIOLOGY/IMMUN/VIROLOGY
  • Organization DUNS
    835607441
  • Organization City
    COLLEGE STATION
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    778454375
  • Organization District
    UNITED STATES